PET-determined prevalence of coronary microvascular dysfunction and different types in a cardio-metabolic risk population.

Background: he aim was to investigate the prevalence of (predominantly related to alterations in hyperemic MBFs) and (predominantly related to alterations in resting MBF) normal coronary microvascular function (nCMF) or coronary microvascular dysfunction (CMD) in a clinical population without flow-limiting obstructive CAD.

Methods: We prospectively enrolled 239 symptomatic patients with normal pharmacologically-stress and rest myocardial perfusion on N-ammonia PET/CT. N-ammonia PET/CT concurrently assessed myocardial flow reserve (MFR = MBF stress/MBF rest).

Coronary circulatory function with increasing obesity: A complex U-turn.

Aims: The aim of this investigation was to explore and characterize alterations in coronary circulatory function in function of increasing body weight with medically controlled cardiovascular risk factors and, thus, "metabolically" unhealthy obesity.

Materials And Methods: We prospectively enrolled 106 patients with suspected CAD but with normal stress-rest myocardial perfusion on N-ammonia PET/CT and with medically controlled or no cardiovascular risk factors. N-ammonia PET/CT concurrently determined myocardial blood flow (MBF) during pharmacologically induced hyperaemia and at rest.

F-FDG PET in Myocardial Viability Assessment: A Practical and Time-Efficient Protocol.

We assessed image quality using a practical and time-efficient protocol for intravenous glucose loading and insulin injection before administration of F-FDG for PET myocardial viability evaluation in patients with ischemic cardiomyopathy (ICM), with and without type 2 diabetes mellitus. The metabolic preparation period (MPP) or optimal cardiac F-FDG uptake was determined from the time of intravenous infusion of 12.5 or 25 g of 50% dextrose to the time of F-FDG injection.

Cardiovascular magnetic resonance with an MR compatible pacemaker.

Magnetic resonance imaging (MRI) within FDA guidelines for the MRI-conditional pacemaker precludes placing the heart at the center of the magnet's bore. This in effect appears to preclude cardiovascular MR. In this manuscript, we describe a protocol for cardiovascular MR of patients with a Revo pacemaker system while operating within FDA guidelines, and the first US case of cardiovascular MR in a patient with a Revo MRI-conditional pacing system despite position constraints.